HRP20110332T1 - TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3 - Google Patents
TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3 Download PDFInfo
- Publication number
- HRP20110332T1 HRP20110332T1 HR20110332T HRP20110332T HRP20110332T1 HR P20110332 T1 HRP20110332 T1 HR P20110332T1 HR 20110332 T HR20110332 T HR 20110332T HR P20110332 T HRP20110332 T HR P20110332T HR P20110332 T1 HRP20110332 T1 HR P20110332T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- branched
- unbranched
- atom
- groups
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims 2
- 102000008161 Adenosine A3 Receptor Human genes 0.000 title 1
- 108010060261 Adenosine A3 Receptor Proteins 0.000 title 1
- OCSVDRXXLBXUJM-UHFFFAOYSA-N triazolo[1,5-a]quinoline Chemical class C1=CC=C2N3N=NC=C3C=CC2=C1 OCSVDRXXLBXUJM-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 85
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 80
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 60
- 125000005843 halogen group Chemical group 0.000 claims abstract 46
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract 44
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 41
- 150000001875 compounds Chemical class 0.000 claims abstract 39
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 32
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 31
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 31
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims abstract 30
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 28
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims abstract 27
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 21
- 125000002541 furyl group Chemical group 0.000 claims abstract 20
- 125000001544 thienyl group Chemical group 0.000 claims abstract 20
- -1 methylenedioxy group Chemical group 0.000 claims abstract 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 13
- 125000003277 amino group Chemical group 0.000 claims abstract 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 8
- 125000002252 acyl group Chemical group 0.000 claims abstract 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims 36
- 239000012453 solvate Substances 0.000 claims 35
- 150000001204 N-oxides Chemical class 0.000 claims 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 238000002483 medication Methods 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000008569 process Effects 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 102100036006 Adenosine receptor A3 Human genes 0.000 claims 3
- 101710128949 Adenosine receptor A3 Proteins 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003852 triazoles Chemical class 0.000 claims 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000029549 Muscle injury Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 241000159243 Toxicodendron radicans Species 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 210000005091 airway smooth muscle Anatomy 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 1
- 230000001088 anti-asthma Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000001384 anti-glaucoma Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000002253 anti-ischaemic effect Effects 0.000 claims 1
- 230000000648 anti-parkinson Effects 0.000 claims 1
- 230000003356 anti-rheumatic effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000005095 gastrointestinal system Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 150000007529 inorganic bases Chemical class 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 230000007302 negative regulation of cytokine production Effects 0.000 claims 1
- 230000005455 negative regulation of mast cell degranulation Effects 0.000 claims 1
- 230000007658 neurological function Effects 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 150000007530 organic bases Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004354 sulfur functional group Chemical group 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0700395A HUP0700395A2 (en) | 2007-06-07 | 2007-06-07 | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
| PCT/HU2008/000063 WO2008149168A1 (en) | 2007-06-07 | 2008-06-02 | Triazolo [1, 5-a] quinolines as adenosine a3 receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110332T1 true HRP20110332T1 (hr) | 2011-06-30 |
Family
ID=89987565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110332T HRP20110332T1 (hr) | 2007-06-07 | 2011-05-06 | TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3 |
Country Status (45)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2766643C (en) | 2009-07-08 | 2017-01-03 | Dermira (Canada), Inc. | Tofa analogs useful in treating dermatological disorders or conditions |
| FR3053968A1 (fr) * | 2016-07-13 | 2018-01-19 | Biomerieux | Reactifs pour la protection reversible de molecules biologiques |
| WO2018054357A1 (zh) * | 2016-09-24 | 2018-03-29 | 山东亨利医药科技有限责任公司 | 含盐皮质激素受体拮抗剂的药物组合物及其用途 |
| KR20200139153A (ko) | 2018-02-27 | 2020-12-11 | 인사이트 코포레이션 | A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘 |
| MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
| TWI851441B (zh) | 2018-07-05 | 2024-08-01 | 美商英塞特公司 | 作為a2a/a2b抑制劑之稠合吡嗪衍生物 |
| AU2019385905B2 (en) | 2018-11-30 | 2023-01-12 | Merck Sharp & Dohme Llc | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
| JP7414827B2 (ja) | 2018-12-20 | 2024-01-16 | インサイト・コーポレイション | アクチビン受容体様キナーゼ－２の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479759A (en) * | 1974-11-23 | 1977-07-13 | Lepetit Spa | Heterocyclic fused derivatives of indole and quinoline |
| GR76063B (ar) * | 1981-04-03 | 1984-08-03 | Roussel Uclaf | |
| ZA836701B (en) * | 1982-10-01 | 1984-10-31 | Roussel Uclaf | Imidazo(1,2-a)quinolines |
| GB0108475D0 (en) | 2001-04-04 | 2001-05-23 | Merck Sharp & Dohme | New compounds |
| EP1390349B1 (en) * | 2001-05-31 | 2012-07-25 | Sanofi | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| CA2471087A1 (en) | 2001-12-21 | 2003-07-03 | Jsw-Research Forschungslabor Gmbh | Pyrazolyl-substituted triazoloquinoxalines |
| HUP0105406A3 (en) * | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| JP2007500689A (ja) * | 2003-07-31 | 2007-01-18 | サノフイ−アベンテイス | アミノキノリン誘導体およびアデノシンａ３リガンドとしてのそれらの使用 |
-
2007
- 2007-06-07 HU HU0700395A patent/HUP0700395A2/hu unknown
-
2008
- 2008-02-06 UA UAA200913976A patent/UA99463C2/ru unknown
- 2008-06-02 ES ES08762666T patent/ES2363672T3/es active Active
- 2008-06-02 KR KR1020107000342A patent/KR20100031610A/ko not_active Application Discontinuation
- 2008-06-02 AU AU2008259534A patent/AU2008259534B2/en not_active Ceased
- 2008-06-02 RU RU2009149518/04A patent/RU2489432C2/ru not_active IP Right Cessation
- 2008-06-02 CN CN2008800191923A patent/CN101679272B/zh not_active Expired - Fee Related
- 2008-06-02 CA CA002689612A patent/CA2689612A1/en not_active Abandoned
- 2008-06-02 ME MEP-2009-340A patent/ME00958B/me unknown
- 2008-06-02 SI SI200830255T patent/SI2167470T1/sl unknown
- 2008-06-02 DK DK08762666.9T patent/DK2167470T3/da active
- 2008-06-02 WO PCT/HU2008/000063 patent/WO2008149168A1/en active Application Filing
- 2008-06-02 EP EP08762666A patent/EP2167470B1/en active Active
- 2008-06-02 DE DE602008005589T patent/DE602008005589D1/de active Active
- 2008-06-02 PT PT08762666T patent/PT2167470E/pt unknown
- 2008-06-02 JP JP2010510891A patent/JP5487100B2/ja not_active Expired - Fee Related
- 2008-06-02 MY MYPI20095180A patent/MY148654A/en unknown
- 2008-06-02 PL PL08762666T patent/PL2167470T3/pl unknown
- 2008-06-02 NZ NZ581186A patent/NZ581186A/en not_active IP Right Cessation
- 2008-06-02 MX MX2009013209A patent/MX2009013209A/es active IP Right Grant
- 2008-06-02 AT AT08762666T patent/ATE502016T1/de active
- 2008-06-02 BR BRPI0812257-1A2A patent/BRPI0812257A2/pt not_active IP Right Cessation
- 2008-06-05 JO JO2008263A patent/JO2689B1/ar active
- 2008-06-05 PA PA20088782901A patent/PA8782901A1/es unknown
- 2008-06-05 CL CL200801648A patent/CL2008001648A1/es unknown
- 2008-06-05 PE PE2008000960A patent/PE20090325A1/es not_active Application Discontinuation
- 2008-06-05 AR ARP080102391A patent/AR066873A1/es not_active Application Discontinuation
- 2008-06-06 TW TW097121025A patent/TWI424998B/zh not_active IP Right Cessation
- 2008-06-06 UY UY31130A patent/UY31130A1/es not_active Application Discontinuation
-
2009
- 2009-11-13 TN TNP2009000482A patent/TN2009000482A1/fr unknown
- 2009-11-20 GT GT200900301A patent/GT200900301A/es unknown
- 2009-11-23 ZA ZA2009/08280A patent/ZA200908280B/en unknown
- 2009-11-24 SV SV2009003420A patent/SV2009003420A/es unknown
- 2009-12-02 IL IL202471A patent/IL202471A0/en unknown
- 2009-12-03 NI NI200900210A patent/NI200900210A/es unknown
- 2009-12-04 DO DO2009000276A patent/DOP2009000276A/es unknown
- 2009-12-04 US US12/631,139 patent/US8338411B2/en active Active
- 2009-12-04 EC EC2009009783A patent/ECSP099783A/es unknown
- 2009-12-04 HN HN2009003357A patent/HN2009003357A/es unknown
- 2009-12-16 CR CR11171A patent/CR11171A/es unknown
-
2010
- 2010-01-06 CO CO10001036A patent/CO6270233A2/es active IP Right Grant
- 2010-01-07 MA MA32498A patent/MA31738B1/fr unknown
- 2010-04-29 HK HK10104249.9A patent/HK1138581A1/xx not_active IP Right Cessation
-
2011
- 2011-05-06 HR HR20110332T patent/HRP20110332T1/hr unknown
- 2011-05-30 CY CY20111100519T patent/CY1111644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110332T1 (hr) | TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3 | |
| JP2009529047A5 (ar) | ||
| JP5978293B2 (ja) | Ｎａｍｐｔを阻害するための新規な化合物および組成物 | |
| JP5524071B2 (ja) | 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト | |
| HRP20171748T1 (hr) | 6-amino kinazolina ili 3-cijano derivati kinolina, postupci priprave i njihova farmaceutska uporaba | |
| KR20010050223A (ko) | Ｃｒｆ 길항제 및 관련 조성물의 용도 | |
| BR112013004773B1 (pt) | Compostos, seus usos, e composições para a inibição de nampt | |
| AU2006297124A1 (en) | 2-amino-7,8-dihydro-6H-pyrido(4,3-d) pyrimidin-5-ones | |
| US9181238B2 (en) | N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors | |
| CN103596568A (zh) | 治疗帕金森病的方法以及组合物 | |
| BRPI0610382A2 (pt) | inibidores de sinalização de receptor de vegf e receptor de hgf | |
| KR20100087291A (ko) | 케모카인 수용체 길항제로서의 옥타하이드로펜탈렌 화합물 | |
| AU2016252860B2 (en) | Compositions and methods for inhibiting kinases | |
| JP2015518895A (ja) | Ｅｇｆｒ活性を調節するための化合物および組成物 | |
| CN104725356B (zh) | 氮杂环衍生物及其在药物中的应用 | |
| WO2010126082A1 (ja) | 運動障害治療剤 | |
| CA3137985A1 (en) | Substituted pyrrolo [2, 3-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | |
| CN108530444A (zh) | 一种新型nampt和ido双重抑制剂及其制备方法和医药用途 | |
| ES2263039T3 (es) | Derivados de imidazoquinolina como ligandos del receptor a3 de adenosina. | |
| US10835535B2 (en) | Certain protein kinase inhibitors | |
| JP5663485B2 (ja) | 不安障害治療剤 | |
| CN110156782B (zh) | 作为pi3k/mtor抑制剂的吡啶基取代的稠合喹啉化合物 | |
| US11793821B2 (en) | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors | |
| CN1972917B (zh) | 氨基嘧啶类化合物及其盐和其制备方法与药物用途 | |
| RU2448959C2 (ru) | Би-арил-мета-пиримидиновые ингибиторы киназы |